Understanding the basis of drug resistance of the mutants of αβ-tubulin dimer via molecular dynamics simulations

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Natarajan, Kathiresan ^a   Senapati, Sanjib ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TUBULIN; ANTINEOPLASTIC AGENT; ARGININE; BETA TUBULIN; DIMER; EPOTHILONE A; EPOTHILONE DERIVATIVE; GLUTAMIC ACID; GLUTAMINE; ISOLEUCINE; LIGAND; MUTANT PROTEIN; PACLITAXEL; PROTEIN; THREONINE;

ARTICLE; CONTROLLED STUDY; DRUG PROTEIN BINDING; DRUG RESISTANCE; MICROTUBULE; MOLECULAR DOCKING; MOLECULAR DYNAMICS; POINT MUTATION; PROTEIN CONFORMATION; PROTEIN STRUCTURE; SIMULATION;

AMINO ACIDS; ANTINEOPLASTIC AGENTS; BINDING SITES; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; HUMANS; MOLECULAR DYNAMICS SIMULATION; MUTANT PROTEINS; MUTATION; PACLITAXEL; PROTEIN MULTIMERIZATION; THERMODYNAMICS; TUBULIN;

EID: 84864660051     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0042351     Document Type: Article

References (43)

1. Conde C, Caceres A, (2009) Microtubule assembly, organization and dynamics in axons and dendrites. Nat Rev Neurosci 10: 319-332.
2. Hammond JW, Cai D, Verhey KJ, (2008) Tubulin modifications and their cellular functions. Curr Opin Cell Biol 20: 71-76.
3. Verhey KJ, Gaetig J, (2007) The tubulin code. Cell Cycle 6: 2152-2160.
4. Jordan MA, Wilson L, (2004) Microtubules as a target for cancer therapy. Nature Rev Cancer 4: 253-265.
5. Perez EA, (2009) Microtubule inhibitors: differentiating tubulin-inhibiting agents based on mechanism of action, clinical activity, and resistance. Mol Cancer Ther 8: 2086-2095.
6. Kavallaris M, (2010) Microtubules and resistance to tubulin-binding agents. Nature Rev Cancer 10: 1-11.
7. Kingston DGI, Bane S, Sydner JP, (2005) The taxol pharmacophore and the t-taxol bridging principle. Cell cycle 4: 279-289.
8. Goodin S, Kane MP, Rubin EH, (2004) Epothilones: mechanism of action and biological activity. J Clin Onc 22: 2015-2025.
9. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, et al. (1995) Epothilones, a new class of microtubule-stabilizing agents with a Taxol-like mechanism of action. Cancer Res 55: 2325-2333.
10. He L, Jagtap PG, Kingston DG, Shen HJ, Orr GA, et al. (2000) A common pharmacophore for taxol and the epothilones based on the biological activity of a taxane molecule lacking a C-13 side chain. Biochemistry 39: 3972-3978.
11. Ojima I, Chakravarty S, Inoue T, Lin S, He L, et al. (1999) A common pharmacophore for cytotoxic natural products that stabilize microtubules. Proc Nat. Acad Sci U S A 96: 4256-4261.
12. Forli S, Manetti F, Altman KH, Botta M, (2010) Evaluation of novel epothilone analogues by means of a common pharmacophore and QSAR pseudorecepter model for taxanes and epothilone. Chem Med Chem 5: 35-40.
13. Lowe J, Li H, Downing KH, Nogales E, (2001) Refined structure of αβ-tubulin at 3.5Å resolution. J Mol Biol 313: 1045-57.
14. Nettles JH, Li H, Cornett B, Krahn JM, Snyder JP, et al. (2004) The binding mode of epothilone A on α,β-tubulin by electron crystallography. Science 305: 866-869.
15. Wang Y, O'Brate A, Zhou W, Giannakakou P, (2005) Resistance to microtubule-stabilizing drugs involves two events: β-tubulin mutation in one allele followed by loss of second allele. Cell Cycle 4: 1847-1853.
16. Mozzetti S, Lantomasi R, Maria ID, Prislei S, Mariani M, et al. (2008) Molecular mechanism of patupilone resistance. Cancer Res 68: 10197-10204.
17. Hasegawa S, Miyoshi Y, Egawa C, Ishitobi M, Tamaki Y, et al. (2002) Mutational analysis of the class I β-tubulin gene in human breast cancer. Int J Cancer 101: 46-51.
18. Gonzalez-Garay ML, Chang L, Blade K, Menick DR, Cabral F, (1999) A β-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. J Biol Chem 274: 23875-23882.
19. Monzo M, Rosell R, Sanchez JJ, Lee JS, O'Brate A, et al. (1999) Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations. J Clin Oncol 17: 1786-1793.
20. Giannakakou P, Sackett DL, Kang YK, Zhan Z, Buters JT, et al. (1997) Paclitaxel-resistant human ovarian cancer cells have mutant-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 272: 17118-17125.
21. Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, et al. (2000) A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci U S A 97: 2904-2909.
22. He L, Yang CP, Horwitz SB, (2001) Mutations in β-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. Mol Cancer Ther 1: 3-10.
23. Yang CH, Verdier-Pinard P, Wang F, Lippaine-Horvath E, He L, et al. (2005) A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence. Mol Cancer Ther 4: 987-995.
24. Verrillis NM, Flemming CL, Liu M, Ivery MT, Cobon CS, et al. (2003) Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem Biol 10: 597-607.
25. Insight II, (1996) Accelrys Inc.: San Diego CA.
26. Case DA, Darden TA, Cheatham TE, Simmerling CL, Wang J, et al. (2010) Amber 11. University of California, San Francisco.
27. Vriend G, (1990) WHAT IF: a molecular modeling and drug design program. J Mol Graph 8: 52-56.
28. Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, et al. (2009) Gaussian 09, revision A.1; Gaussian Inc.: Wallingford CT.
29. Cornell WD, Cieplak P, Bayly CI, Kollmann PA, (1993) Application of RESP charges to calculate conformational energies, hydrogen bond energies, and free energies of solvation. J Am Chem Soc 115: 9620-9631.
30. Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, et al. (1995) A smooth particle mesh Ewald method. J Chem Phys 103: 8577-8593.
31. Phillips JC, Braun R, Wang W, Gumbart J, Tajkhorshid E, et al. (2005) Scalable molecular dynamics with NAMD. J Comput Chem 26: 1781-1802.
32. Hornak V, Abel R, Okur A, Strockbine B, Roitberg A, et al. (2006) Comparison of multiple amber force fields and development of improved protein backbone parameters. Proteins 65: 712-725.
33. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, et al. (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comp Chem 30: 2785-2791.
34. Huey R, Morris GM, Olson AJ, Goodsell DS, (2007) A semiempirical free energy force field with charge-based desolvation. J Comp Chem 28: 1145-1152.
35. Kollman PA, Massova I, Reyes C, Kuhn B, Huo S, et al. (2000) Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. Acc Chem Res 33: 889-897.
36. Srinivasan J, Cheatham TE, Cieplak P, Kollman PA, Case DA, (1998) Continuum solvent studies of the stability of DNA, RNA, and phosphoramidate-DNA helices. J Am Chem Soc 120: 9401-9409.
37. Gilson MK, Zhou HX, (2007) Calculation of protein-ligand binding affinities. Annu Rev Biophys Biomol Struc 36: 21-42.
38. Perakyla M, Nordman N, (2001) Energetic analysis of binding of progesterone and 5β-androstane-3,17-dione to anti progesterone antibody DB3 using molecular dynamics and free energy calculations. Prot Eng 14: 753-758.
39. Mitra A, Sept D, (2008) Taxol allosterically alters the dynamics of the tubulin dimer and increases the flexibility of microtubules. Biophys J 95: 3252-3258.
40. Alasdair T, Laurie R, Jackson RM, (2005) Q-SiteFinder: an energy based method for the prediction of protein-ligand binding sites. Bioinformatics 9: 1908-1916.
41. Sobolev V, Sorokine A, Prilusky J, Abola EE, Edelman M, (1999) Automated analysis of interatomic contacts in proteins. Bioinformatics 15: 327-332.
42. Li Y, Edsali RJ, Jagtap PG, Kingston DG, Bane S, (2000) Equilibrium studies of a fluorescent paclitaxel derivative binding to microtubules. Biochemistry 39: 616-623.
43. Kowalski J, Giannakakou P, Hamel J, (1997) Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R). 272: 2534-2541.